Tetracyclic Dopamine Ligands for Selective D3 Receptor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dopamine receptor-targeting drugs often exhibit significant side effects due to their action on D2 receptors, whereas D3 receptors have a different localization and lower expression, suggesting a need for compounds that preferentially target D3 receptors to minimize these side effects.
Innovation Solution
Development of tetracyclic compounds with a specific trans configuration, which act as potent dopamine ligands with preferential affinity for D3 receptors, reducing their interaction with D2 receptors, and their preparation process involving various chemical reactions to achieve these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dopamine receptor-targeting drugs act on D2 receptors, then therapeutic effects are achieved, but side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (tetracyclic framework with particular substituent patterns at positions 4, 4a, and 11b) that confer selective affinity for D3 receptors over D2 receptors. This structural differentiation enables the drug to target specific receptor subtypes locally, achieving therapeutic effects while minimizing off-target side effects associated with non-selective D2 receptor activation
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including the tetracyclic core structure, substituent types (alkyl, cycloalkyl, aryl groups), and stereochemical configuration (trans-4a,11b-dimethyl configuration). These parameter modifications optimize the compound's binding affinity selectivity ratio between D3 and D2 receptors, enhancing therapeutic effectiveness while reducing side effects through improved receptor selectivity
2Object-generated harmful factors
If compounds are designed to preferentially target D3 receptors, then side effects are reduced, but affinity for D2 receptors decreases
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (tetracyclic framework with particular substituent patterns at positions 4, 4a, and 11b) that confer selective affinity for D3 receptors over D2 receptors. This structural differentiation enables the drug to target specific receptor subtypes locally, achieving therapeutic effects while minimizing off-target side effects associated with non-selective D2 receptor activation
Solution Approach 2:
The patent applies partial action by designing compounds with moderate to high affinity for D3 receptors that is selectively greater than their affinity for D2 receptors. The compounds achieve sufficient dopaminergic activity through preferential D3 receptor engagement, particularly in limbic regions, while the reduced D2 receptor interaction naturally limits side effects. This partial selectivity approach balances therapeutic effectiveness with safety
Data Source
AI summary
Tetracyclic compound (I), its racemic and optical isomeric forms, addition salts with acids and hydrates, are new. Tetracyclic compound of formula (I), its racemic and optical isomeric forms, addition salts with acids and hydrates, are new. X : O or NR 2 (preferred); Y 1-CH 2- (preferred), -(CH 2) 2- or -CH=CH-; R 1, R 2H, 1-6C alkyl, 3-8C cycloalkyl or 3-8C cycloalkyl-1-6C alkyl, preferably R 1 is alkyl. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Neuroprotective; CNS-Gen; Antiparkinsonian; Endocrine-Gen; Antidepressant; Tranquilizer; Nootropic; Cerebroprotective; Vasotropic. MECHANISM OF ACTION : Dopminergic receptor binder. The affinity of (I) to bind with human dopaminergic receptors was tested. The results showed that (4aRS,11bRS)4-propyl-3,4,4a,5,6,8,9,11b-octahydroisoindolo[5,6-h][1,4]benzoxazin-10(2H)-one exhibited a negative log of inhibition constant (pKi) of 8.1 and 5.9, respectively against D3 and D2 dopaminergic receptors.